{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:18:57Z","timestamp":1792801137600,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2024J01693, 2022J01282"],"award-info":[{"award-number":["2024J01693, 2022J01282"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2024J01693, 2022J01282"],"award-info":[{"award-number":["2024J01693, 2022J01282"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2024J01693, 2022J01282"],"award-info":[{"award-number":["2024J01693, 2022J01282"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2024J01693, 2022J01282"],"award-info":[{"award-number":["2024J01693, 2022J01282"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2024J01693, 2022J01282"],"award-info":[{"award-number":["2024J01693, 2022J01282"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2024J01693, 2022J01282"],"award-info":[{"award-number":["2024J01693, 2022J01282"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2024J01693, 2022J01282"],"award-info":[{"award-number":["2024J01693, 2022J01282"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2024J01693, 2022J01282"],"award-info":[{"award-number":["2024J01693, 2022J01282"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2024J01693, 2022J01282"],"award-info":[{"award-number":["2024J01693, 2022J01282"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Startup Fund for Scientific Research of Fujian Medical University","award":["2022QH11104"],"award-info":[{"award-number":["2022QH11104"]}],"id":[{"id":"https:\/\/ror.org\/050s6ns64","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Innovation and Entrepreneurship Training Program for Undergraduates of Fujian Medical University","award":["C2024189"],"award-info":[{"award-number":["C2024189"]}],"id":[{"id":"https:\/\/ror.org\/050s6ns64","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Innovation and Entrepreneurship Training Program for Undergraduates of Fujian Medical University","award":["C2024189"],"award-info":[{"award-number":["C2024189"]}],"id":[{"id":"https:\/\/ror.org\/050s6ns64","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Open Fund of Fujian Provincial Key Laboratory of Plasma and Magnetic Resonance","award":["20191203"],"award-info":[{"award-number":["20191203"]}]},{"name":"Open Fund of Fujian Provincial Key Laboratory of Plasma and Magnetic Resonance","award":["20191203"],"award-info":[{"award-number":["20191203"]}]},{"name":"Open Fund of Key Laboratory of OptoElectronic Science and Technology for Medicine of Ministry of Education","award":["JYG2203"],"award-info":[{"award-number":["JYG2203"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute myeloid leukemia (AML) remains a challenging hematological malignancy, with chemoresistance contributing significantly to treatment failure and relapse. The bone marrow microenvironment, particularly mesenchymal stem cells (MSCs), plays a critical role in AML cell survival and drug resistance. Although previous studies have extensively explored the MSCs differentiation, the regulatory role of the adipogenically differentiated MSCs on AML cells during co-culture remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An indirect co-culture model was established to evaluate the impact of MSCs on the drug sensitivity of AML cells. Based on the comparable chemosensitivity trends observed among THP-1, U937, and HL-60 cells, THP-1 were selected for subsequent experiments due to their stable growth characteristics and well-established utilization. Metabolic alterations between co-cultured and monocultured THP-1 were profiled using nuclear magnetic resonance spectroscopy. Concurrently, RNA sequencing was conducted to identify differentially expressed genes and enriched signaling pathways between co-cultured and monocultured THP-1. To validate the pathway alterations identified by transcriptomic analysis, the Akt inhibitor MK-2206 was applied, and its effects were evaluated by western blotting and cell viability assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The results demonstrated that AML cells co-cultured with adipogenic MSCs were less sensitive to daunorubicin and cytarabine in both in vitro and in vivo. Subsequent metabolomics analysis revealed significant alternative metabolic processes in AML cells following co-culture, specifically in the glycolysis, glutamine metabolism and lipid metabolism. Further transcriptomic profiling identified key differentially expressed genes and signaling pathways, with PI3K\/Akt signaling pathway activation emerging as a contributor to the reduced chemotherapy sensitivity. Furthermore, elevated levels of IL-6 in the co-culture system suggested a role for cytokine-mediated signaling in promoting a protective microenvironment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This work demonstrates that the adipogenically differentiated MSCs enhance the survival and chemoresistance of AML cells by modulating metabolic and signaling pathways. It provides integrated insights into the microenvironment-driven mechanisms of AML drug resistance and presents potential therapeutic targets to enhance treatment efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03550-0","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:32:32Z","timestamp":1760700752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrated metabolomic and transcriptomic analysis identifies adipogenic differentiation of mesenchymal stem cells as a driver of chemoresistance in acute myeloid leukemia"],"prefix":"10.1186","volume":"44","author":[{"given":"Zhipeng","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haishan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"3550_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","volume":"14","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Borthakur G, Daver N, DiNardo CD, Issa G, Jabbour E, et al. Current status and research directions in acute myeloid leukemia. Blood Cancer J. 2024;14:163. https:\/\/doi.org\/10.1038\/s41408-024-01143-2.","journal-title":"Blood Cancer J"},{"key":"3550_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"key":"3550_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijo.2023.5567","volume":"63","author":"Y Tian","year":"2023","unstructured":"Tian Y, Lei Y, Wang Y, Lai J, Wang J, Xia F. Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein. Int J Oncol. 2023;63:1\u201319. https:\/\/doi.org\/10.3892\/ijo.2023.5567.","journal-title":"Int J Oncol"},{"key":"3550_CR4","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1194\/jlr.M091876","volume":"60","author":"SF Tan","year":"2019","unstructured":"Tan SF, Dunton W, Liu X, Fox TE, Morad SA, Desai D, et al. Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-\u03baB-dependent P-glycoprotein upregulation. J Lipid Res. 2019;60:1078\u201386. https:\/\/doi.org\/10.1194\/jlr.M091876.","journal-title":"J Lipid Res"},{"key":"3550_CR5","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/s41375-020-0710-7","volume":"34","author":"B Yan","year":"2020","unstructured":"Yan B, Chen Q, Xu J, Li W, Xu B, Qiu Y. Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia. Leukemia. 2020;34:1816\u201327. https:\/\/doi.org\/10.1038\/s41375-020-0710-7.","journal-title":"Leukemia"},{"key":"3550_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-021-00233-2","volume":"10","author":"Y Yao","year":"2021","unstructured":"Yao Y, Li F, Huang J, Jin J, Wang H. Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development. Exp Hematol Oncol. 2021;10:39. https:\/\/doi.org\/10.1186\/s40164-021-00233-2.","journal-title":"Exp Hematol Oncol"},{"key":"3550_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature12984","volume":"505","author":"SJ Morrison","year":"2014","unstructured":"Morrison SJ, Scadden DT. The bone marrow niche for Haematopoietic stem cells. Nature. 2014;505:327\u201334. https:\/\/doi.org\/10.1038\/nature12984.","journal-title":"Nature"},{"key":"3550_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach P, Trumpp A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica. 2023;108:353. https:\/\/doi.org\/10.3324\/haematol.2022.280800.","journal-title":"Haematologica"},{"key":"3550_CR9","doi-asserted-by":"publisher","first-page":"8404","DOI":"10.1038\/s41598-024-58860-8","volume":"14","author":"HK Palani","year":"2024","unstructured":"Palani HK, Ganesan S, Balasundaram N, Venkatraman A, Korula A, Abraham A, et al. Ablation of Wnt signaling in bone marrow stromal cells overcomes microenvironment-mediated drug resistance in acute myeloid leukemia. Sci Rep. 2024;14:8404. https:\/\/doi.org\/10.1038\/s41598-024-58860-8.","journal-title":"Sci Rep"},{"key":"3550_CR10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1182\/blood.2020009845","volume":"138","author":"G Borella","year":"2021","unstructured":"Borella G, Da Ros A, Borile G, Porc\u00f9 E, Tregnago C, Benetton M, et al. Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia. Blood. 2021;138:557\u201370. https:\/\/doi.org\/10.1182\/blood.2020009845.","journal-title":"Blood"},{"key":"3550_CR11","doi-asserted-by":"publisher","unstructured":"Lis LE, Pievani A, Garc\u00eda M, Forte D, Williams TL, Serafini M, et al. Bone marrow mesenchymal stromal cells support translation in refractory acute myeloid leukemia. Cell Rep. 2025;44. https:\/\/doi.org\/10.1016\/j.celrep.2024.115151.","DOI":"10.1016\/j.celrep.2024.115151"},{"key":"3550_CR12","doi-asserted-by":"publisher","first-page":"5164","DOI":"10.1182\/bloodadvances.2020004041","volume":"5","author":"M Chiu","year":"2021","unstructured":"Chiu M, Taurino G, Dander E, Bardelli D, Fallati A, Andreoli R, et al. ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment. Blood Adv. 2021;5:5164\u201378. https:\/\/doi.org\/10.1182\/bloodadvances.2020004041.","journal-title":"Blood Adv"},{"key":"3550_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1182\/blood-2015-07-655860","volume":"128","author":"R Moschoi","year":"2016","unstructured":"Moschoi R, Imbert V, Nebout M, Chiche J, Mary D, Prebet T, et al. Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. Blood. 2016;128:253\u201364. https:\/\/doi.org\/10.1182\/blood-2015-07-655860.","journal-title":"Blood"},{"key":"3550_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cmet.2020.09.001","volume":"32","author":"D Forte","year":"2020","unstructured":"Forte D, Garc\u00eda M, Sanchez A, Stavropoulou V, Fielding C, Mart\u00edn D, et al. Bone marrow mesenchymal stem cells support acute myeloid leukemia bioenergetics and enhance antioxidant defense and escape from chemotherapy. Cell Metab. 2020;32:829\u201343. https:\/\/doi.org\/10.1016\/j.cmet.2020.09.001.","journal-title":"Cell Metab"},{"key":"3550_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3324\/haematol.2020.269944","volume":"107","author":"HR Lee","year":"2021","unstructured":"Lee HR, Lee GY, Kim EW, Kim HJ, Lee M, Humphries RK, et al. Reversible switching of leukemic cells to a drugresistant, stem-like subset via IL-4-mediated cross-talk with mesenchymal stroma. Haematologica. 2021;107:381. https:\/\/doi.org\/10.3324\/haematol.2020.269944.","journal-title":"Haematologica"},{"key":"3550_CR16","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1111\/cas.15855","volume":"114","author":"J Lu","year":"2023","unstructured":"Lu J, Dong Q, Zhang S, Feng Y, Yang J, Zhao L. Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6\/JAK2\/STAT3 signaling. Cancer Sci. 2023;114:3287\u2013300. https:\/\/doi.org\/10.1111\/cas.15855.","journal-title":"Cancer Sci"},{"key":"3550_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40164-021-00220-7","volume":"10","author":"T Lyu","year":"2021","unstructured":"Lyu T, Wang Y, Li D, Yang H, Qin B, Zhang W, et al. Exosomes from BM-MSCs promote acute myeloid leukemia cell proliferation, invasion and chemoresistance via upregulation of S100A4. Exp Hematol Oncol. 2021;10:24. https:\/\/doi.org\/10.1186\/s40164-021-00220-7.","journal-title":"Exp Hematol Oncol"},{"key":"3550_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s13287-021-02444-0","volume":"12","author":"L Zhang","year":"2021","unstructured":"Zhang L, Chi Y, Wei Y, Zhang W, Wang F, Zhang L, et al. Bone marrow-derived mesenchymal stem\/stromal cells in patients with acute myeloid leukemia reveal transcriptome alterations and deficiency in cellular vitality. Stem Cell Res Ther. 2021;12:365. https:\/\/doi.org\/10.1186\/s13287-021-02444-0.","journal-title":"Stem Cell Res Ther"},{"key":"3550_CR19","doi-asserted-by":"publisher","first-page":"5944","DOI":"10.1038\/s41598-021-85122-8","volume":"11","author":"MT Weickert","year":"2021","unstructured":"Weickert MT, Hecker JS, Buck MC, Schreck C, Rivi\u00e8re J, Schiemann M, et al. Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression. Sci Rep. 2021;11:5944. https:\/\/doi.org\/10.1038\/s41598-021-85122-8.","journal-title":"Sci Rep"},{"key":"3550_CR20","doi-asserted-by":"publisher","first-page":"e75908","DOI":"10.7554\/eLife.75908","volume":"11","author":"N Vilaplana","year":"2022","unstructured":"Vilaplana N, Cuminetti V, Almaghrabi R, Papatzikas G, Rout AK, Jeeves M, et al. Crosstalk between AML and stromal cells triggers acetate secretion through the metabolic rewiring of stromal cells. eLife. 2022;11:e75908. https:\/\/doi.org\/10.7554\/eLife.75908.","journal-title":"eLife"},{"key":"3550_CR21","doi-asserted-by":"publisher","first-page":"102900","DOI":"10.1016\/j.redox.2023.102900","volume":"67","author":"H Li","year":"2023","unstructured":"Li H, Wang Y, Yang F, Feng S, Chang K, Yu X, et al. Clonal MDS\/AML cells with enhanced TWIST1 expression reprogram the differentiation of bone marrow MSCs. Redox Biol. 2023;67:102900. https:\/\/doi.org\/10.1016\/j.redox.2023.102900.","journal-title":"Redox Biol"},{"key":"3550_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41375-019-0568-8","volume":"34","author":"M Azadniv","year":"2020","unstructured":"Azadniv M, Myers JR, McMurray HR, Guo N, Rock P, Coppage ML, et al. Bone marrow mesenchymal stromal cells from acute myelogenous leukemia patients demonstrate adipogenic differentiation propensity with implications for leukemia cell support. Leukemia. 2020;34:391\u2013403. https:\/\/doi.org\/10.1038\/s41375-019-0568-8.","journal-title":"Leukemia"},{"key":"3550_CR23","doi-asserted-by":"publisher","first-page":"2105811","DOI":"10.1002\/advs.202105811","volume":"9","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhao Q, Cang H, Wang Z, Hu X, Pan R, et al. Acute myeloid leukemia cells educate mesenchymal stromal cells toward an adipogenic differentiation propensity with leukemia promotion capabilities. Adv Sci. 2022;9:2105811. https:\/\/doi.org\/10.1002\/advs.202105811.","journal-title":"Adv Sci"},{"key":"3550_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1126\/science.284.5411.143","volume":"284","author":"MF Pittenger","year":"1999","unstructured":"Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143\u20137. https:\/\/doi.org\/10.1126\/science.284.5411.143.","journal-title":"Science"},{"key":"3550_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, Slaper I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8:315\u20137. https:\/\/doi.org\/10.1080\/14653240600855905.","journal-title":"Cytotherapy"},{"key":"3550_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.stem.2014.01.013","volume":"14","author":"M Mendicino","year":"2014","unstructured":"Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR. MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell. 2014;14:141\u20135. https:\/\/doi.org\/10.1016\/j.stem.2014.01.013.","journal-title":"Cell Stem Cell"},{"key":"3550_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14:417\u20139. https:\/\/doi.org\/10.1038\/nmeth.4197.","journal-title":"Nat Methods"},{"key":"3550_CR28","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"M Kanehisa","year":"2017","unstructured":"Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45:D353\u201361. https:\/\/doi.org\/10.1093\/nar\/gkw1092.","journal-title":"Nucleic Acids Res"},{"key":"3550_CR29","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51:D587\u201392. https:\/\/doi.org\/10.1093\/nar\/gkac963.","journal-title":"Nucleic Acids Res"},{"key":"3550_CR30","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","volume":"18","author":"SA Jones","year":"2018","unstructured":"Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18:773\u201389. https:\/\/doi.org\/10.1038\/s41577-018-0066-7.","journal-title":"Nat Rev Immunol"},{"key":"3550_CR31","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1186\/s12885-019-6057-7","volume":"19","author":"JH Kim","year":"2019","unstructured":"Kim JH, Kim WS, Park C. Interleukin-6 mediates resistance to PI3K-pathway\u2013targeted therapy in lymphoma. BMC Cancer. 2019;19:936. https:\/\/doi.org\/10.1186\/s12885-019-6057-7.","journal-title":"BMC Cancer"},{"key":"3550_CR32","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.3390\/cells11223698","volume":"11","author":"M Ra\u0161kov\u00e1","year":"2022","unstructured":"Ra\u0161kov\u00e1 M, Lacina L, Kej\u00edk Z, Venhauerova A, Skali\u010dkov\u00e1 M, Kol\u00e1\u0159 M, et al. The role of IL-6 in cancer cell invasiveness and metastasis\u2014overview and therapeutic opportunities. Cells. 2022;11:3698. https:\/\/doi.org\/10.3390\/cells11223698.","journal-title":"Cells"},{"key":"3550_CR33","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1089\/scd.2012.0621","volume":"22","author":"F Chen","year":"2013","unstructured":"Chen F, Zhou K, Zhang L, Ma F, Chen D, Cui J, et al. Mesenchymal stem cells induce granulocytic differentiation of acute promyelocytic leukemic cells via IL-6 and MEK\/ERK pathways. Stem Cells Dev. 2013;22:1955\u201367. https:\/\/doi.org\/10.1089\/scd.2012.0621.","journal-title":"Stem Cells Dev"},{"key":"3550_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13046-019-1081-7","volume":"38","author":"W Zhong","year":"2019","unstructured":"Zhong W, Zhu Z, Xu X, Zhang H, Xiong H, Li Q, et al. Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels. J Exp Clin Cancer Res. 2019;38:73. https:\/\/doi.org\/10.1186\/s13046-019-1081-7.","journal-title":"J Exp Clin Cancer Res"},{"key":"3550_CR35","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/leu.2015.325","volume":"30","author":"S Geyh","year":"2016","unstructured":"Geyh S, Rodriguez M, J\u00e4ger P, Khandanpour C, Cadeddu RP, Gutekunst J, et al. Functional Inhibition of mesenchymal stromal cells in acute myeloid leukemia. Leukemia. 2016;30:683\u201391. https:\/\/doi.org\/10.1038\/leu.2015.325.","journal-title":"Leukemia"},{"key":"3550_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-018-1013-z","volume":"9","author":"G Corradi","year":"2018","unstructured":"Corradi G, Baldazzi C, O\u010dadl\u00edkov\u00e1 D, Marconi G, Parisi S, Testoni N, et al. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival. Stem Cell Res Ther. 2018;9:1\u201315. https:\/\/doi.org\/10.1186\/s13287-018-1013-z.","journal-title":"Stem Cell Res Ther"},{"key":"3550_CR37","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","volume":"21","author":"I Mart\u00ednez","year":"2021","unstructured":"Mart\u00ednez I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21:669\u201380. https:\/\/doi.org\/10.1038\/s41568-021-00378-6.","journal-title":"Nat Rev Cancer"},{"key":"3550_CR38","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.tcb.2022.11.004","volume":"33","author":"G Egan","year":"2023","unstructured":"Egan G, Schimmer AD. Contribution of metabolic abnormalities to acute myeloid leukemia pathogenesis. Trends Cell Biol. 2023;33:455\u201362. https:\/\/doi.org\/10.1016\/j.tcb.2022.11.004.","journal-title":"Trends Cell Biol"},{"key":"3550_CR39","doi-asserted-by":"publisher","first-page":"115759","DOI":"10.1016\/j.bcp.2023.115759","volume":"216","author":"JL Carter","year":"2023","unstructured":"Carter JL, Su Y, Qiao X, Zhao J, Wang G, Howard M, et al. Acquired resistance to venetoclax plus Azacitidine in acute myeloid leukemia: In vitro models and mechanisms. Biochem Pharmacol. 2023;216:115759. https:\/\/doi.org\/10.1016\/j.bcp.2023.115759.","journal-title":"Biochem Pharmacol"},{"key":"3550_CR40","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun M, Zhang G, Yang J, Chen K, Xu W, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6:425. https:\/\/doi.org\/10.1038\/s41392-021-00828-5.","journal-title":"Signal Transduct Target Ther"},{"key":"3550_CR41","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22:138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6.","journal-title":"Mol Cancer"},{"key":"3550_CR42","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/aps.2016.121","volume":"38","author":"L Deng","year":"2017","unstructured":"Deng L, Jiang L, Lin X, Tseng K, Liu Y, Zhang X, et al. The PI3K\/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia. Acta Pharmacol Sin. 2017;38:382\u201391. https:\/\/doi.org\/10.1038\/aps.2016.121.","journal-title":"Acta Pharmacol Sin"},{"key":"3550_CR43","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.3390\/ijms21082907","volume":"21","author":"I Nepstad","year":"2020","unstructured":"Nepstad I, Hatfield KJ, Gr\u00f8nnings\u00e6ter IS, Reikvam H. The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells. Int J Mol Sci. 2020;21:2907. https:\/\/doi.org\/10.3390\/ijms21082907.","journal-title":"Int J Mol Sci"},{"key":"3550_CR44","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.3390\/jcm9092934","volume":"9","author":"S Darici","year":"2020","unstructured":"Darici S, Alkhaldi H, Horne G, J\u00f8rgensen HG, Marmiroli S, Huang X. Targeting PI3K\/Akt\/mTOR in AML: rationale and clinical evidence. J Clin Med. 2020;9:2934. https:\/\/doi.org\/10.3390\/jcm9092934.","journal-title":"J Clin Med"},{"key":"3550_CR45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.canlet.2012.09.020","volume":"329","author":"L Jin","year":"2013","unstructured":"Jin L, Tabe Y, Lu H, Borthakur G, Miida T, Kantarjian H, et al. Mechanisms of apoptosis induction by simultaneous Inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer Lett. 2013;329:45\u201358. https:\/\/doi.org\/10.1016\/j.canlet.2012.09.020.","journal-title":"Cancer Lett"},{"key":"3550_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41392-019-0050-0","volume":"4","author":"I Nepstad","year":"2019","unstructured":"Nepstad I, Hatfield KJ, Gr\u00f8nnings\u00e6ter IS, Aaseb\u00f8 E, Hernandez M, Hagen KM, et al. Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. Signal Transduct Target Ther. 2019;4:20. https:\/\/doi.org\/10.1038\/s41392-019-0050-0.","journal-title":"Signal Transduct Target Ther"},{"key":"3550_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41419-021-03504-2","volume":"12","author":"C Zhou","year":"2021","unstructured":"Zhou C, Du J, Zhao L, Liu W, Zhao T, Liang H, et al. GLI1 reduces drug sensitivity by regulating cell cycle through PI3K\/AKT\/GSK3\/CDK pathway in acute myeloid leukemia. Cell Death Dis. 2021;12:231. https:\/\/doi.org\/10.1038\/s41419-021-03504-2.","journal-title":"Cell Death Dis"},{"key":"3550_CR48","doi-asserted-by":"publisher","first-page":"113192","DOI":"10.1016\/j.yexcr.2022.113192","volume":"417","author":"H Liu","year":"2022","unstructured":"Liu H, Hussain Z, Xie Q, Yan X, Zeng C, Zhou G, et al. Targeting PI3K\/AKT\/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax. Exp Cell Res. 2022;417:113192. https:\/\/doi.org\/10.1016\/j.yexcr.2022.113192.","journal-title":"Exp Cell Res"},{"key":"3550_CR49","doi-asserted-by":"publisher","first-page":"110626","DOI":"10.1016\/j.cellsig.2023.110626","volume":"105","author":"X Chu","year":"2023","unstructured":"Chu X, Zhong L, Dan W, Wang X, Zhang Z, Liu Z, et al. DNMT3A R882H mutation promotes acute leukemic cell survival by regulating Glycolysis through the NRF2\/NQO1 axis. Cell Signal. 2023;105:110626. https:\/\/doi.org\/10.1016\/j.cellsig.2023.110626.","journal-title":"Cell Signal"},{"key":"3550_CR50","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41586-018-0622-0","volume":"562","author":"MJ Bollong","year":"2018","unstructured":"Bollong MJ, Lee G, Coukos JS, Yun H, Zambaldo C, Chang JW, et al. A metabolite-derived protein modification integrates Glycolysis with KEAP1\u2013NRF2 signalling. Nature. 2018;562:600\u20134. https:\/\/doi.org\/10.1038\/s41586-018-0622-0.","journal-title":"Nature"},{"key":"3550_CR51","doi-asserted-by":"publisher","first-page":"111652","DOI":"10.1016\/j.biopha.2021.111652","volume":"142","author":"C Cheng","year":"2021","unstructured":"Cheng C, Yuan F, Chen XP, Zhang W, Zhao XL, Jiang ZP, et al. Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C. Biomed Pharmacother. 2021;142:111652. https:\/\/doi.org\/10.1016\/j.biopha.2021.111652.","journal-title":"Biomed Pharmacother"},{"key":"3550_CR52","doi-asserted-by":"publisher","first-page":"8340","DOI":"10.1182\/blood-2022-171050","volume":"140","author":"S Cao","year":"2022","unstructured":"Cao S, Wang J, Pan C, Zheng L, Shang Q. Nrf2 overexpression increases risk of venetoclax resistance in acute myeloid leukemia by promoting Glycolysis. Blood. 2022;140:8340\u20138340. https:\/\/doi.org\/10.1182\/blood-2022-171050.","journal-title":"Blood"},{"key":"3550_CR53","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1128\/mcb.10.5.2327-2334.1990","volume":"10","author":"TA Libermann","year":"1990","unstructured":"Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-\u03baB transcription factor. Mol Cell Biol. 1990;10:2327\u201334. https:\/\/doi.org\/10.1128\/mcb.10.5.2327-2334.1990.","journal-title":"Mol Cell Biol"},{"key":"3550_CR54","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ctrv.2012.04.007","volume":"38","author":"Y Guo","year":"2012","unstructured":"Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38:904\u201310. https:\/\/doi.org\/10.1016\/j.ctrv.2012.04.007.","journal-title":"Cancer Treat Rev"},{"key":"3550_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-6057-7","volume":"19","author":"JH Kim","year":"2019","unstructured":"Kim JH, Kim WS, Park C. Interleukin-6 mediates resistance to PI3K-pathway\u2013targeted therapy in lymphoma. BMC Cancer. 2019;19:1\u201311. https:\/\/doi.org\/10.1186\/s12885-019-6057-7.","journal-title":"BMC Cancer"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03550-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03550-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03550-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:32:34Z","timestamp":1760700754000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03550-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3550"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03550-0","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Biomedical Research Ethics Review Committee of Fujian Medical University. And informed consent was obtained from all subjects involved in the study. The project was titled as \u201cThe mechanism and clinical research value of FTO regulation of bone marrow MSCs adipogenic differentiation in AML chemotherapy resistance (No. 2024\u2009\u2212\u2009121)\u201d, and was approved on 06\/03\/2024. The animal experiments were in line with the regulations promulgated by the Laboratory Animal Welfare & Ethics Committee of Fujian Medical University. The project was titled as \u201cThe mechanism and clinical research value of FTO regulation of bone marrow MSCs adipogenic differentiation in AML chemotherapy resistance (IACUCFJMU 2024-Y-0624)\u201d, and was approved on 08\/03\/2024.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have not used AI-generated work in this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of AI and AI-assisted technologies in the writing process"}}],"article-number":"291"}}